MAM
YMAB

Meeder Asset Management’s Y-mAbs Therapeutics YMAB Stock Holding History

Meeder Asset Management’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,867
Closed -$81K – 2404
2020
Q2 		$81K Buy
1,867
+1,454
+352% +$55K 0.01% 808
2020
Q1 		$11K Sell
413
-5,892
-93% -$171K ﹤0.01% 1493
2019
Q4 		$196K Buy
+6,305
New +$187K 0.01% 609

Other funds holding YMAB

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Meeder Asset Management's YMAB Position: Q3 2020 in Review

Meeder Asset Management sold out of Y-mAbs Therapeutics (YMAB) in Q3 2020, closing a stake of 1,867 shares — an estimated $81K sold.

Meeder Asset Management first reported a position in YMAB in Q4 2019 and held it in 3 quarters. The position peaked at $196K in Q4 2019. 106 funds tracked by Wall St. Rank hold YMAB as of Q3 2020.

  • Meeder Asset Management reported no remaining Y-mAbs Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Meeder Asset Management sold 1,867 Y-mAbs Therapeutics shares in Q3 2020, an estimated $81K.
  • Meeder Asset Management first reported a position in Y-mAbs Therapeutics in Q4 2019 and held it in 3 quarters.
  • Meeder Asset Management's Y-mAbs Therapeutics position peaked at $196K in Q4 2019.
  • 106 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2020.

Based on Meeder Asset Management's 13F filing for Q3 2020, filed 2 Nov 2020.